Program
Autologous TP53 R175H Mutant-specific HLA-A*02:01-restricted TCR Gene Engineered T-lymphocytes NT-175
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AstraZeneca.
Furthest: phase 1, since May 17, 20231 company-led study, 1 open or runningNext primary completion: Jul 31, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 1since May 17, 2023 | May 17, 2023 | Jul 31, 2029phase 1 · NCT05877599 |
- Named in AstraZeneca’s own pipeline as
NT-175
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05877599 · 45 planned · United States
Ahead
- Jul 31, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05877599
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted TP53 (p53) R175H mutant, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and r…”NCIt, read by Claude
Other programs on TP53
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025rule | clasp-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05877599Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Jul 31, 2029 | 45 |
How it is read
Names in the registry
- “NT-175”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.